Last reviewed · How we verify
NCT04216277: PARI
The Procalcitonin Guided Antibiotics in Respiratory Infections in General Practice
NA trial testing Procalcitonin in Acute Respiratory Tract Infection. Withdrawn.
1 August 2022
Quick facts
| Lead sponsor | Chronic Obstructive Pulmonary Disease Trial Network, Denmark |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | diagnostic |
| Start date | 27 February 2020 |
| Primary completion | 1 August 2022 |
| Estimated completion | 1 August 2022 |
| Sites | 6 locations across Denmark |
Drugs / interventions tested
- Procalcitonin — full drug profile →
Conditions studied
- Acute Respiratory Tract Infection — all drugs for Acute Respiratory Tract Infection →
Sponsor
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Who can join
18 and older, any sex, with Acute Respiratory Tract Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Antimicrobial resistance rates have reached alarming levels and the Worlds Health Organisation (WHO) states it constitutes a serious public health concern by threatening one of the most effective and mortality lowering interventions in modern medicine. Part of the solution to this problem includes minimizing overuse of antibiotics. But clinical signs alone are often not reliable to guide antibiotic treatment decisions and additional tests may be warranted to assist the doctor. Such tests include point-of-care biomarkers of infection like C-reactive protein (CRP) and procalcitonin (PCT). Targeting antibiotic use to the few patients with a high probability of benefit and withholding in the many with non-serious respiratory infection is a promising strategy and readily implemented in clinical practice. The Procalcitonin guided Antibiotics in Respiratory Infections (PARI) study will assess the effect of a novel point-of-care PCT guided antibiotic stewardship in acute respiratory tract infections in general practice. The overall aim of the PARI study is to reduce antibiotic use in patients with acute respiratory tract infections by targeting antibiotic treatment only to patients with a suspected bacterial etiology and thus likely to benefit from antibiotic therapy. The main research questions are: Does the addition of a point-of-care Procalcitonin test to standard care reduce antibiotic use in primary care? Is the intervention safe for the patients? The PARI study is a pragmatic two-arm (intervention and control (standard care) open randomized non-inferiority trial (up to 1 day difference in recovery) in general practice.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Biomarkers as point-of-care tests to guide prescription of antibiotics in people with acute respiratory infections in primary care.
Smedemark SA, Aabenhus R, Llor C, Fournaise A, et al · · 2022 · cited 66× · PMID 36250577 · DOI 10.1002/14651858.cd010130.pub3 -
The Procalcitonin-guided Antibiotics in Respiratory Infections (PARI) project in general practice - a study protocol.
Filipsen N, Bro H, Bjerrum L, Jensen JS, et al · · 2022 · cited 2× · PMID 35279069 · DOI 10.1186/s12875-022-01646-6
Verify or expand the search:
- PubMed search for NCT04216277
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Procalcitonin
Trials testing the same drug.
- NCT06253325 — Early Detection of At-risk Septic Patients · recruiting
- NCT04634188 — Role and Value of Inflammatory Markers in Brain Tumors : A Case Controlled Study · completed
- NCT03191071 — An Algorithm to Decide on Antibiotic Prescription in Lower Respiratory Tract Infection in Primary Care · NA · completed
- NCT02899065 — Evaluation of the Roche Liat Flu/RSV Assay for Management of Influenza in the Emergency Department · NA · completed
- NCT03058718 — Procalcitonin-Guided Antibiotic Therapy in Bronchiectasis · NA · completed
Other recruiting trials for Acute Respiratory Tract Infection
Currently open trials in the same condition.
- NCT05814237 — POS-ARI-ER Observational Study of Acute Respiratory Infections · recruiting
Other Chronic Obstructive Pulmonary Disease Trial Network, Denmark trials
Trials by the same sponsor.
- NCT05563675 — Once Daily Long-Acting Muscarinic Antagonists Administered in the Evening for Prevention of Chronic Obstructive Pulmonar · Phase 4 · completed
- NCT04481555 — Eosinophil-guided Reduction of Inhaled Corticosteroids · Phase 4 · completed
- NCT04322396 — Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19 · Phase 2 · terminated
- NCT04538976 — Copd Exacerbation and Pulmonary Hypertension Trial · Phase 4 · completed
- NCT03262142 — Targeted AntiBiotics for Chronic Pulmonary Diseases · Phase 4 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04216277 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chronic Obstructive Pulmonary Disease Trial Network, Denmark
- Last refreshed: 27 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04216277.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing